

Clinical trials of erythropoietin

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
erythropoietin vs placebo			
REVEAL [NCT00378352] n=NA follow-up:	Single parenteral administration of erythropoietin at 15,000 Units, 30,000 Units, or 60,000 Units versus placebo	patients after large myocardial infarction	parallel groups double-blind
recombinant human erythropoietin beta vs placebo			
REVIVAL-3 [NCT00390832] n=NA follow-up:	recombinant human erythropoietin beta 33.333 IU given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) versus placebo	patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention	double-blind Germany

More details and results :

- increasing hemoglobin concentration for acute myocardial infarction in patients undergoing PCI at <http://www.trialresultscenter.org/go-Q470>

References

REVEAL, :

Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011 May 11;305:1863-72 [21558517] [10.1001/jama.2011.592](https://doi.org/10.1001/jama.2011.592)

REVIVAL-3, :

Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010;3:408-13 [20736448] [10.1161/CIRCINTERVENTIONS.109.904425](https://doi.org/10.1161/CIRCINTERVENTIONS.109.904425)

Stappich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. BMC Cardiovasc Disord 2017;17:38 [28109258]

Steppich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. BMC Cardiovasc Disord 2017;17:38 [28109258]

2 heart failure

Trial	Treatments	Patients	Trials design and methods
beta-erythropoietin vs placebo			
Palazzuoli , 2006 n=20/20 follow-up:	s.c. beta-EPO for 3 months twice weekly and oral iron versus placebo + oral iron	patients with anemia and resistant CHF	double blind

More details and results :

- increasing hemoglobin concentration for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q301>

References

Palazzuoli, 2006:

Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabr A, Campagna SM, Nuti R Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096.e9-15 [17161060]